
Can the Right Intervention for Hearing Loss Slow Neuroinflammation?
In the three-year ACHIEVE trial, GFAP, a neuroinflammation-related biomarker, rose more slowly in older adults who received a comprehensive hearing intervention than in the control group.
Auditory Scene
































